I remember that also, i remember being a little upset that it sounded like whatever trial we did do for Nash would only lead to another in order to prove the concept. I thought the first trial would do that. my guess is that the conversation started with the first trial and the potential partners said do more and then we will talk. I don't understand this as it seems Nash drugs get rolling on a lot les than what Leronlimab already has. Lets keep in mind the safety aspects are done - other drugs have to prove efficacy and safety.

I don't think partnerships, licenses and buyout talks are very near term, the quietness to me is just quietness. Antonio is not pushing anything and the BOD is just being excessively safe in the eyes of the SEC and FDA. Investors should demand more for there investment in this company as we are wasting time. It could be deals are eminent, however i will believe it when i see it. One the other hand, nobody has predicted anything correctly for years with this company so who knows, my guess is just that.